Yelena Ginzburg is an Oncology physician affiliated with Mount Sinai Health System. OpenAlex indexes 151 publications with 4,355 citations (h-index 33).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20252 payments
- GENZYME CORPORATIONProgram year20253 payments
- Celgene CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Jakafi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- Modulating Iron Trafficking to Ameliorate Ineffective Erythropoiesis in MDS
Icahn School of Medicine at Mount Sinai
FY2026$871,028R01DK143032 - The Role of Erythroferrone in Regulating Bone Metabolism in Beta-Thalassemia
Icahn School of Medicine at Mount Sinai
FY2025$570,650R01DK107670 - The Role of Erythroferrone in Regulating Bone Metabolism in Beta-Thalassemia
Icahn School of Medicine at Mount Sinai
FY2024$543,541R01DK107670
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
New England Journal of Medicine
2024 - Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
Journal of Medicinal Chemistry
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Stamatios Lerakis, MD
Mount Sinai Health System
Stanley Yancovitz, MD
Mount Sinai Health System
Vivek Yerrapu Reddy
Mount Sinai Health System
Robert Desnick, PhD, MD
Mount Sinai Health System
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”